This new technology combines SiMSen Seq with Two-Tailed PCR for precison diagnosis of cancer and other diseases. Enables very small amount of DNA sequences, in liquid biopsies, to be analyzed for specific tumor disease and to tailor it’s therapy.
Impact: Offers possibility for early liquid biopsy diagnosis, but also to customize pharma therapy for patients.
Simsen contact: Pontus Rehn
GUV contact: Anders Waas
